Logo

People in the News: Andy Page

Jul 03, 2012
Premium

23andMe has named Andy Page to its board of directors. He currently serves as president of Gilt Group. Previously he served as chief operating and financial officer at PlayPhone; chief financial officer and senior vice president of business strategy at StubHub; and has held senior executive positions at Panasas, ONI Systems, and Robertson Stephens & Company.

He holds a BA from Princeton University and an MBA from Harvard Business School.

Filed under

Clinical Sequencing
Sequencing
Diagnostics
Next-Generation Sequencing
23andMe
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.